EVI5L 억제제

EVI5L inhibitors encompass a range of compounds that can indirectly influence the function of EVI5L as a GTPase-activating protein. These modulators primarily target various aspects of GTPase signaling pathways, either by inhibiting specific GTPases or by affecting upstream or downstream components of these pathways. Inhibitors like NSC 23766 Trihydrochloride and ML 141 target specific GTPases such as Rac1 and Cdc42. By modulating these GTPases, these compounds can indirectly influence the broader signaling pathways in which EVI5L operates. Brefeldin A and SecinH3 affect the ARF GTPase family, either by disrupting GEF activity or inhibiting cytohesins. These alterations in GTPase signaling pathways can have downstream effects on the functions regulated by GTPase-activating proteins like EVI5L.

Statins, including Lovastatin and Simvastatin, and specific inhibitors like Farnesyltransferase Inhibitors (Tipifarnib) and Geranylgeranyltransferase Inhibitors (GGTI 298), impact the prenylation and localization of GTPases. Such modifications can indirectly affect the signaling pathways involving EVI5L. In summary, while direct inhibitors of EVI5L are not well-documented, the compounds listed provide avenues to modulate the GTPase pathways and related signaling mechanisms where EVI5L is involved. These inhibitors are valuable tools for investigating EVI5L's role in cellular signaling, providing insights into its biological functions.